Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 8 5 versus AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 8 5 versus AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER.
AMINOSYN 8.5% vs AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 8.5% is a crystalline amino acid solution that provides a source of nitrogen and essential/non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It serves as a substrate for metabolic pathways, including gluconeogenesis and ketogenesis, and supports immune function and enzyme production.
Provides essential amino acids and dextrose for parenteral nutrition; amino acids serve as substrates for protein synthesis, while dextrose supplies caloric energy.
Intravenous infusion: 1.0-1.5 g amino acids/kg/day (11.8-17.6 mL/kg/day of 8.5% solution) via central line; rate not to exceed 0.1 g amino acids/kg/hour.
Individualized based on protein and calorie requirements; typical adult dose: 500-2000 mL/day intravenously, infused at a rate not exceeding 200 mL/hour.
None Documented
None Documented
Variable; amino acids have rapid distribution and metabolic half-lives of minutes to hours; terminal half-life of infused amino acid mixtures is approximately 1–2 hours for most components in patients with normal hepatic function
Variable, dependent on individual amino acids and metabolic state; clinical context reflects continuous infusion without distinct terminal phase.
Renal elimination of infused amino acids as urea, ammonia, and other nitrogenous waste products; minimal biliary/fecal excretion (<2%)
Renal, primarily as urea and free amino acids; minimal biliary/fecal elimination.
Category C
Category C
Amino Acid Solution
Amino Acid Solution